Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Boehringer Ingelheim...

    Boehringer Ingelheim to restructure executive board

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-27T09:30:37+05:30  |  Updated On 27 Aug 2019 9:30 AM IST
    Boehringer Ingelheim to restructure executive board

    Allan Hillgrove, head of pharmaceuticals and biopharma and a company veteran of 37 years, will retire at the end of the year and will be replaced by Carine Brouillon, who joined unlisted Boehringer from Johnson & Johnson(JnJ) in 2018.


    Frankfurt: German drugmaker Boehringer Ingelheim will enter next year with a new-look executive board after the retirement of two of its top executives and another of the positions on the six-person executive board becoming redundant.


    Allan Hillgrove, head of pharmaceuticals and biopharma and a company veteran of 37 years, will retire at the end of the year and will be replaced by Carine Brouillon, who joined unlisted Boehringer from Johnson & Johnson(JnJ) in 2018.


    The head of Boehringer's animal health unit, Joachim Hasenmaier, will also retire at the end of the year, to be succeeded by Jean Scheftsik de Szolnok, currently head of Boehringer's French business.


    Boehringer became the world's second-largest animal health company when it acquired Sanofi's Merial business in 2017 but it is set to drop a place in the ranking when Elanco wraps up its agreed purchase of Bayer's veterinary drugs business next year.


    Read Also: Boehringer collaborates with MD Anderson to form virtual RnD center to advance new cancer therapies


    Boehringer added that head of personnel Andreas Neumann would quit at the end of September because responsibilities for human resources will be shared by Chief Executive Hubertus von Baumbach and finance chief Michael Schmelmer.


    A company spokesman declined to comment whether the departures were connected or coincidental.


    Read Also: Boehringer buys up AMAL Therapeutics, eyes oncology combo strategy

    Allan HillgroveAndreas NeumannbiopharmaBoehringer IngelheimCarine Brouillongerman drugmakerHubertus von BaumbachJean Scheftsik de SzolnokJnJJoachim HasenmaierJohnson & JohnsonMichael Schmelmerpharmapharma companypharma newsSanofi
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok